RNS Number : 2933S
Fusion Antibodies PLC
07 July 2020

Fusion Antibodies plc
("Fusion" or the "Company")

Exercise of Options

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that has made an application to the London Stock Exchange for the admission to trading on AIM ("Admission") of 12,500 new ordinary shares of 4p each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued pursuant to the exercise of options by an employee of the Company. The options were granted pursuant to the Company's Historic Option Scheme (as defined in the Company's admission document dated 12 December 2017) and have an exercise price of 4p per option. The New Ordinary Shares will rank *pari passu* in all respects with the Company's existing ordinary shares and Admission is expected to become effective on or around 13 July 2020.

Total Voting Rights

On Admission, the issued share capital of the Company will consist of 25,437,025 Ordinary Shares, with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 25,437,025. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer *Via Walbrook PR*
James Fair, Chief Financial Officer

Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai

Walbrook PR

Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com

Anna Dunphy
Mob: +44 (0)7876 741 001

Paul McManus
Mob: +44 (0)7980 541 893

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^{TM} platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 100 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEMZGGNFNGGGZM